325 related articles for article (PubMed ID: 29472271)
1. TNFα and Radioresistant Stromal Cells Are Essential for Therapeutic Efficacy of Cyclic Dinucleotide STING Agonists in Nonimmunogenic Tumors.
Francica BJ; Ghasemzadeh A; Desbien AL; Theodros D; Sivick KE; Reiner GL; Hix Glickman L; Marciscano AE; Sharabi AB; Leong ML; McWhirter SM; Dubensky TW; Pardoll DM; Drake CG
Cancer Immunol Res; 2018 Apr; 6(4):422-433. PubMed ID: 29472271
[TBL] [Abstract][Full Text] [Related]
2. Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity.
Corrales L; Glickman LH; McWhirter SM; Kanne DB; Sivick KE; Katibah GE; Woo SR; Lemmens E; Banda T; Leong JJ; Metchette K; Dubensky TW; Gajewski TF
Cell Rep; 2015 May; 11(7):1018-30. PubMed ID: 25959818
[TBL] [Abstract][Full Text] [Related]
3. STING-Dependent Cytosolic DNA Sensing Promotes Radiation-Induced Type I Interferon-Dependent Antitumor Immunity in Immunogenic Tumors.
Deng L; Liang H; Xu M; Yang X; Burnette B; Arina A; Li XD; Mauceri H; Beckett M; Darga T; Huang X; Gajewski TF; Chen ZJ; Fu YX; Weichselbaum RR
Immunity; 2014 Nov; 41(5):843-52. PubMed ID: 25517616
[TBL] [Abstract][Full Text] [Related]
4. Refractoriness of STING therapy is relieved by AKT inhibitor through effective vascular disruption in tumour.
Jeong SH; Yang MJ; Choi S; Kim J; Koh GY
Nat Commun; 2021 Jul; 12(1):4405. PubMed ID: 34285232
[TBL] [Abstract][Full Text] [Related]
5. Effective delivery of STING agonist using exosomes suppresses tumor growth and enhances antitumor immunity.
McAndrews KM; Che SPY; LeBleu VS; Kalluri R
J Biol Chem; 2021; 296():100523. PubMed ID: 33711340
[TBL] [Abstract][Full Text] [Related]
6. STING activation of tumor endothelial cells initiates spontaneous and therapeutic antitumor immunity.
Demaria O; De Gassart A; Coso S; Gestermann N; Di Domizio J; Flatz L; Gaide O; Michielin O; Hwu P; Petrova TV; Martinon F; Modlin RL; Speiser DE; Gilliet M
Proc Natl Acad Sci U S A; 2015 Dec; 112(50):15408-13. PubMed ID: 26607445
[TBL] [Abstract][Full Text] [Related]
7. Discovery of IACS-8803 and IACS-8779, potent agonists of stimulator of interferon genes (STING) with robust systemic antitumor efficacy.
Ager CR; Zhang H; Wei Z; Jones P; Curran MA; Di Francesco ME
Bioorg Med Chem Lett; 2019 Oct; 29(20):126640. PubMed ID: 31500996
[TBL] [Abstract][Full Text] [Related]
8. Identification of Novel Carbocyclic Pyrimidine Cyclic Dinucleotide STING Agonists for Antitumor Immunotherapy Using Systemic Intravenous Route.
Vyskocil S; Cardin D; Ciavarri J; Conlon J; Cullis C; England D; Gershman R; Gigstad K; Gipson K; Gould A; Greenspan P; Griffin R; Gulavita N; Harrison S; Hu Z; Hu Y; Hata A; Huang J; Huang SC; Janowick D; Jones M; Kolev V; Langston SP; Lee HM; Li G; Lok D; Ma L; Mai D; Malley J; Matsuda A; Mizutani H; Mizutani M; Molchanova N; Nunes E; Pusalkar S; Renou C; Rowland S; Sato Y; Shaw M; Shen L; Shi Z; Skene R; Soucy F; Stroud S; Xu H; Xu T; Abu-Yousif AO; Zhang J
J Med Chem; 2021 May; 64(10):6902-6923. PubMed ID: 34000802
[TBL] [Abstract][Full Text] [Related]
9. A STING Agonist Given with OX40 Receptor and PD-L1 Modulators Primes Immunity and Reduces Tumor Growth in Tolerized Mice.
Foote JB; Kok M; Leatherman JM; Armstrong TD; Marcinkowski BC; Ojalvo LS; Kanne DB; Jaffee EM; Dubensky TW; Emens LA
Cancer Immunol Res; 2017 Jun; 5(6):468-479. PubMed ID: 28483787
[TBL] [Abstract][Full Text] [Related]
10. STING-dependent cytosolic DNA sensing mediates innate immune recognition of immunogenic tumors.
Woo SR; Fuertes MB; Corrales L; Spranger S; Furdyna MJ; Leung MY; Duggan R; Wang Y; Barber GN; Fitzgerald KA; Alegre ML; Gajewski TF
Immunity; 2014 Nov; 41(5):830-42. PubMed ID: 25517615
[TBL] [Abstract][Full Text] [Related]
11. Biodegradable STING agonist nanoparticles for enhanced cancer immunotherapy.
Wilson DR; Sen R; Sunshine JC; Pardoll DM; Green JJ; Kim YJ
Nanomedicine; 2018 Feb; 14(2):237-246. PubMed ID: 29127039
[TBL] [Abstract][Full Text] [Related]
12. STING Activation and its Application in Immuno-Oncology.
Lian Y; Duffy KJ; Yang J
Curr Top Med Chem; 2019; 19(24):2205-2227. PubMed ID: 31642767
[TBL] [Abstract][Full Text] [Related]
13. Cyclic Dinucleotides Inhibit Osteoclast Differentiation Through STING-Mediated Interferon-β Signaling.
Kwon Y; Park OJ; Kim J; Cho JH; Yun CH; Han SH
J Bone Miner Res; 2019 Jul; 34(7):1366-1375. PubMed ID: 30779854
[TBL] [Abstract][Full Text] [Related]
14. Diminished Innate Antiviral Response to Adenovirus Vectors in cGAS/STING-Deficient Mice Minimally Impacts Adaptive Immunity.
Anghelina D; Lam E; Falck-Pedersen E
J Virol; 2016 Jul; 90(13):5915-27. PubMed ID: 27076643
[TBL] [Abstract][Full Text] [Related]
15. Endosomolytic polymersomes increase the activity of cyclic dinucleotide STING agonists to enhance cancer immunotherapy.
Shae D; Becker KW; Christov P; Yun DS; Lytton-Jean AKR; Sevimli S; Ascano M; Kelley M; Johnson DB; Balko JM; Wilson JT
Nat Nanotechnol; 2019 Mar; 14(3):269-278. PubMed ID: 30664751
[TBL] [Abstract][Full Text] [Related]
16. STING agonists enable antiviral cross-talk between human cells and confer protection against genital herpes in mice.
Skouboe MK; Knudsen A; Reinert LS; Boularan C; Lioux T; Perouzel E; Thomsen MK; Paludan SR
PLoS Pathog; 2018 Apr; 14(4):e1006976. PubMed ID: 29608601
[TBL] [Abstract][Full Text] [Related]
17. The host STING pathway at the interface of cancer and immunity.
Corrales L; McWhirter SM; Dubensky TW; Gajewski TF
J Clin Invest; 2016 Jul; 126(7):2404-11. PubMed ID: 27367184
[TBL] [Abstract][Full Text] [Related]
18. STING activation reprograms tumor vasculatures and synergizes with VEGFR2 blockade.
Yang H; Lee WS; Kong SJ; Kim CG; Kim JH; Chang SK; Kim S; Kim G; Chon HJ; Kim C
J Clin Invest; 2019 Jul; 129(10):4350-4364. PubMed ID: 31343989
[TBL] [Abstract][Full Text] [Related]
19. Novel chemical compound SINCRO with dual function in STING-type I interferon and tumor cell death pathways.
Kimura Y; Negishi H; Matsuda A; Endo N; Hangai S; Inoue A; Nishio J; Taniguchi T; Yanai H
Cancer Sci; 2018 Sep; 109(9):2687-2696. PubMed ID: 29981256
[TBL] [Abstract][Full Text] [Related]
20. STING agonist inflames the pancreatic cancer immune microenvironment and reduces tumor burden in mouse models.
Jing W; McAllister D; Vonderhaar EP; Palen K; Riese MJ; Gershan J; Johnson BD; Dwinell MB
J Immunother Cancer; 2019 Apr; 7(1):115. PubMed ID: 31036082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]